Testing BHV-8000 as a Treatment for Early Parkinson's Disease
Tests BHV-8000 against placebo in adults with early Parkinson's disease.
Plain-language title generated from the registry record
Registry title: A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
Key facts
- Where
- Antwerp, Kortrijk, Leuven, and Liège, BelgiumSee the 4 sites
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 80 years old?
- Has a doctor told you that you have a different condition with similar signs, such as multiple system atrophy or progressive supranuclear palsy?
- How long ago were you diagnosed with Parkinson's disease?
- Which medicine do you take for Parkinson's disease now?
Source: NCT06976268, who can take part
Where in Belgium
- University of AntwerpAntwerp, BelgiumNot yet recruiting
- Algemeen Ziekenhuis GroeningeKortrijk, BelgiumNot yet recruiting
- UZ LeuvenLeuven, BelgiumNot yet recruiting
- Centre Hospitalier Universitaire de LiègeLiège, BelgiumNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Biohaven Therapeutics Ltd.
- Trial code
- NCT06976268EU 2025-521113-13-00
- Record updated
- 22 October 2026
- Original description
A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease. The study will consist of a 48-week double-blind treatment phase followed by a 48-week open-label phase.Read full original descriptionShow less
A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants With Early Parkinson's Disease
A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease. The study will consist of a 48-week double-blind treatment phase followed by a 48-week open-label phase.
Inclusion: Male or female participants 40 to 80 years of age, inclusive, at the time of informed consent; Meet the diagnostic criteria for "Probable PD" as assessed on the Movement Disorder Society (MDS) Clinical Diagnostic Criteria for PD as assessed by the Investigator; Have a clinician-documented diagnosis of idiopathic PD with an onset within 2 years of the Screening Visit.
Exclusion: Treatment with PD medication(s); Medical history indicating a Parkinsonian syndrome other than idiopathic PD, including, but not limited to, progressive supranuclear gaze palsy, multiple system atrophy, drug-induced Parkinsonism, essential tremor, or primary dystonia; Diagnosis of clinically significant central nervous system (CNS) disease other than PD; Any other condition(s) that may compromise participant safety, interfere with study conduct, or jeopardize the potential proper interpretation of study results, in the opinion of the investigator; Participants who are current smokers (defined as smoking [in any form, e.g., tobacco smoke, electronic cigarettes, etc.] ).